PHARMACEUTICAL MARKET RESEARCH REPORTS
Industry Standard Research – ISR Reports – is a full-service pharmaceutical market research company operating exclusively in the life sciences industry and a sister company of Pharmaceutical Online. Their syndicated and custom market research capabilities enable their customers to make smarter, more informed business decisions. You’ll find links to their pharmaceutical market syndicated research reports below.
ISR's market research reports are produced using direct feedback from decision-makers, which enables ISR to provide data on topics that, until now, were only attainable through custom research. With rigorous screening criteria and methodologies that include surveys, in-depth phone interviews, and focus groups, ISR gathers actionable information that is immediately applicable to their customers. Each report is available for to purchase online and you may also download free preview files. If you have any questions, please feel free to email info@ISRreports.com.
TRENDS AND MARKET OUTLOOK REPORTS
-
Oral Dosage Forms Market Overview and Outlook (4th Edition)
This market research report provides an overview of the current market dynamics in the oral dose contract manufacturing space as well as an outlook of what our survey respondents—all oral dose outsourcing decision-makers at sponsor organizations—predict the marketplace will look like in 2024. Key statistics include oral dose project volume, percentage outsourced, and the average number of CMOs used to...
-
Sterile Injectable Drug Product Manufacturing Market Outlook (3rd Ed.)
This report explores which delivery formats drug innovators are using in their pipelines and portfolios, how likely innovators are to outsource manufacturing based on delivery device, and how these proportions will shift over the next five years.
-
Pharmaceutical Excipient Market Overview and Outlook
This market research report offers readers the opportunity to gain insight into the biopharmaceutical excipient market and where it’s heading. Remaining aware of market dynamics and expected changes will enable readers to better make key decisions regarding excipient use and to help identify where competitive advantages may be gained.
-
Development vs Commercial Outsourced Manufacturing Practices: Biologics
This market research report explores how the decision-making process differs among drug innovators outsourcing development activities from those outsourcing commercial manufacturing when it comes to CMO/CDMO selection criteria, use patterns, preferences and perceived leadership.
-
Development vs. Commercial Outsourced Manufacturing Practices: Small Molecule
This report explores how the decision-making process differs among drug innovators outsourcing development activities from those outsourcing commercial manufacturing when it comes to CMO/CDMO selection criteria, use patterns, preferences and perceived leadership.
-
Bioprocessing Market Trends and Outsourcing Dynamics: 2020-2025 (3rd Edition)
This market research report affords readers the opportunity to gain insight into the bioprocessing market and where it’s heading. This report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what our survey respondents predict the marketplace will look like in five years.
-
Clinical Manufacturing Market Dynamics and Service Provider Benchmarking
This report provides an overview of the current market dynamics in the clinical manufacturing space as well as an outlook of what our survey respondents predict the marketplace will look like in 2022.
-
Cell & Gene Therapies Market Outlook
Outsourcing decision-makers for cell or gene therapies at sponsor organizations give an overview of the current market dynamics in the cell & gene therapies contract manufacturing space and predictions through 2026.
CONTRACT MANUFACTURER QUALITY BENCHMARKING
-
Small Molecule API Contract Manufacturer Quality Benchmarking (6th Edition)
This report includes data on 358 service encounters from 123 respondents who have been involved in outsourced small molecule API projects in the past 18 months. It will help biopharma companies make more informed CMO decisions, and help CMOs optimize operational and marketing strategies.
-
Biologic API CDMO Benchmarking (7th Ed.)
This report offers a comprehensive analysis of current outsourcing trends and practices, in addition to a quantitative analysis of CMO service quality across a series of 22 performance attributes.
-
Biologic Drug Product CDMO Benchmarking (5th Ed.)
This report provides pharmaceutical companies and contract manufacturers a comprehensive analysis of current outsourcing trends and practices, in addition to a quantitative analysis of CMO service quality.
-
Small Molecule Drug Product CDMO Benchmarking (5th Ed.)
This report has been designed to help biopharmaceutical companies make more informed CMO decisions, and to help CMOs optimize operational and marketing strategies.
DEPARTMENT MODELS AND STRUCTURES
-
Benchmarking the Pharma Industry’s Market Research Function
ISR conducted five in-depth interviews and 31 online surveys with experienced market researchers in the biopharmaceutical space to gain a better grasp on the market research function. Research subjects shared their insights on the types of research performed, how their market research function is structured, and outsourcing behavior.
-
CDMO Outsourcing Models (3rd Ed.)
This market research report explores how sponsor organizations use contract manufacturers to streamline costs, better manage capacity, access scientific expertise, improve efficiencies and decrease time to market.
-
The CMC Function: Best Practices and Optimization
ISR interviewed 15 CMC professionals at 14 Top 50 pharmaceutical and biotechnology companies, as well as one company outside the Top 50 to better understand the Chemistry Manufacturing and Controls function throughout the preclinical, clinical, and commercialization phases of the product development process.
-
Benchmarking The Pharma Industry’s Medical Science Liaison (MSL) Function
This market research report has been designed to be used as a benchmarking tool for companies to compare their Medical Science Liaison functions to those of other pharmaceutical and biotech organizations. You can purchase a single-user license for individual use, a site-wide license giving access to the report for all employees within...
ISR ARTICLES
-
How Service Providers Can Create Momentum In An Established Brand
To promote brand growth, companies must identify which brand components are succeeding and which may be falling short, as well as understand how these dynamics manifest in the larger organization’s successes and failures.
-
Customer Loyalty In Small Molecule Drug Substance Manufacturing
In Q42021, ISR surveyed 124 sponsors who outsource small molecule drug product to gain insight into customer loyalty. CMO loyalty is computed as an index that consists of overall satisfaction, willingness to recommend, and the likelihood of using the contract manufacturer again. The data below show companies with ten or more responses from recent users and an industry average derived from all CMOs included in the research; their loyalty component scores are aggregated, averaged and then weighted based on the number of customer interactions.
-
Outsourcers Are Feeling Uneasy About Continuity Of Supply
Find out how COVID-19 complications have picked up from the first year, with more outsourcers relaying bigger obstacles when it comes to manufacturing, specifically with drug product.
-
CDMO Preference For Small Molecule Drug Substance
ISR asked API outsourcers which CDMOs they are currently working with and which CDMO they prefer to use for all small molecule drug substance manufacturing. Delve into the data which showed that Cambrex, Patheon, Lonza, STA Pharma and Pfizer CentreOne are the preferred CDMOs among roughly one-third of their current customers.
-
Preference Among Users: New And Emerging Biopharma
In Q3 2021, ISR asked new and emerging biopharma respondents (those with R&D <$500M) which CDMOs they are currently working with, and, if the choice were entirely up to them, which CDMO would they prefer to use for all biologic drug substance manufacturing. Catalent, Lonza, and Patheon lead the pack.
ABOUT ISR VIDEO
WHY ISR?
ISR understands that you’re looking for confidence in your market research. With ISR, you’ll consistently receive:
- Focused Domain Expertise — We’ve operated in pharmaceuticals for over 15 years and because it’s our sole focus, our domain expertise brings value to the work that “generalist” researchers can’t deliver.
- Genuine Research Expertise — Our market research experience has developed over 20 years in many dynamic industries. We capture appropriate sample sizes, given the research objectives, and we use appropriately sophisticated statistics to uncover everything that’s real and to give you confidence in your decisions. Read our Six Questions to Ask About Your Market Research to learn more about why our industry expertise sets us apart.
- Transparency — If you’re like many, you’ve been disappointed more than once by research providers who fail to live up to their promises, providing you with their “professional judgment” in place of sound data; and suspect contacts instead of real decision-makers. We deliver the beliefs, attitudes, and intentions of people who matter – and we’ll prove it by showing you the titles of your respondents.
For additional questions about any of ISR’s reports or custom research services, please contact us at info@ISRreports.com.